Fact Sheet: The 340B Drug Pricing Program

The Issue

For more than 25 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients. These organizations include community health centers, children’s hospitals, hemophilia treatment centers, critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), and public and nonprofit disproportionate share hospitals (DSH) that serve low-income and indigent populations.

The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs.

According to the Health Resources and Services Administration (HRSA), which is responsible for administering the 340B program, enrolled hospitals and other covered entities can achieve average savings of 25 to 50% in pharmaceutical purchases. Despite increased oversight from HRSA and the program’s proven record of decreasing government spending and expanding access to patient care, some want to scale it back or significantly reduce the benefits that eligible hospitals and their patients receive from the program.

AHA Position

  • Believes the 340B program is essential to helping providers stretch limited resources to better serve their vulnerable communities.
  • Supports efforts to rescind the Centers for Medicare & Medicaid Services’ (CMS) drastic payment cuts for many hospitals in the 340B program and expand drug manufacturer transparency.
  • Supports eliminating the orphan drug exclusion for certain 340B hospitals.
  • Opposes efforts to scale back, significantly reduce the benefits of, or expand the regulatory burden of the 340B program, including proposals to dramatically expand reporting requirements on certain 340B hospitals and impose a moratorium on new entrants into the program.
  • Supports expanding the program to reach additional vulnerable communities, including investor-owned hospitals that provide care for underserved populations.
  • Supports voluntary program integrity efforts already underway to ensure this vital program remains available to safety-net providers.

Related Resources

Special Bulletin
The Centers for Medicare & Medicaid Services (CMS) today released the calendar year (CY) 2021 outpatient prospective payment system (OPPS)/ambulatory…
Letter/Comment
Public
AHA expresses concern regarding recent action taken by three major drug manufacturers – Eli Lilly and Co., Merck and Sanofi – to limit the distribution of…
Action Alert
Member
The AHA has developed comments it will submit to the Centers for Medicare & Medicaid Services (CMS) regarding the agency's proposal to collect negotiated…
Action Alert
Member
As Congress considers additional COVID-19 relief actions, we need to make sure hospital and health systems' priorities are at the top of its list. Additional…
Special Bulletin
Member
The Centers for Medicare & Medicaid Services (CMS) May 11 issued its hospital inpatient prospective payment system (PPS) and long-term care hospital (…
Special Bulletin
Member
The Centers for Medicare & Medicaid Services yesterday issued its proposed rule for the inpatient and long-term care hospital prospective payment…